GlassScriptPhysician profile
Kenneth Laxer
NPI 1861460990
$378,909.71
in general payments reported to CMS, 2019-2025
23 companies · $59K in 2025
The $59K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $22K · 2021: $27K · 2022: $100K · 2023: $80K · 2024: $70K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $172K · Travel and Lodging: $26K · Food and Beverage: $7,102 · Consulting Fee: $3,500 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $172,000.00 |
| Travel and Lodging | $25,547.87 |
| Food and Beverage | $7,101.63 |
| Consulting Fee | $3,500.00 |
| Education | $190.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $339,610.82 | 2020-2025 | Xcopri |
| Ucb, INC. | $18,082.20 | 2019-2025 | Nayzilam, Fintepla |
| Livanova USA, INC. | $11,011.98 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Aquestive Therapeutics, INC. | $4,228.13 | 2019-2020 | |
| Eisai INC. | $3,233.41 | 2019 | |
| Neuropace, INC. | $848.12 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $710.33 | 2022-2024 | Epidiolex |
| Neurelis, INC. | $228.06 | 2023-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $202.10 | 2019-2020 | |
| Greenwich Biosciences, INC. | $160.25 | 2019-2021 | |
| Medtronic USA, INC. | $136.23 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $113.86 | 2024 | |
| Amgen INC. | $78.41 | 2019-2021 | |
| Lilly USA, LLC | $64.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $42.44 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $34.55 | 2019 | |
| Neurocrine Biosciences, INC. | $27.91 | 2019 | |
| Medtronic, INC. | $26.62 | 2022 | |
| Avanir Pharmaceuticals, INC. | $20.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.52 | 2019 | |
| Upsher-Smith Laboratories LLC | $18.03 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.73 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Laxer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.